| Topic | Summary of finding | Key genes/disorders in context | Diagnostic tests / pathology clues | Key statistics | Source (year) | DOI / URL | Evidence |
|---|---|---|---|---|---|---|---|
| Histologic definition of sea-blue histiocytes | Sea-blue histiocytes are lipid-laden macrophages with deep blue/blue-green cytoplasmic granules on Romanovsky or May-Grünwald-Giemsa stain; granules reflect lysosomal accumulation of oxidized indigestible lipid/lipoprotein material. | Morphologic finding rather than a single-gene disease entity | Bone marrow aspirate/biopsy; Giemsa stain; PAS and Sudan stains may be positive; autofluorescence and birefringence reported in reviews/case reports | No disease-specific prevalence available | Caetano 2016; Fernández 2023 | https://doi.org/10.23937/2469-5807/1510019 ; https://doi.org/10.48057/hematologa.v27i2.519 | (pqac-00000007, pqac-00000001, pqac-00000011) |
| Primary vs secondary concept | Primary/idiopathic SBHS is rare; secondary sea-blue histiocytosis is more common and occurs with hematologic disorders, lipid storage diseases, hypertriglyceridemia, parenteral nutrition, and drug/toxic exposures. Bhardwaj emphasizes it often “does not signify a distinct entity” but a morphologic marker of underlying disease/high marrow turnover. | Primary SBHS; secondary forms linked to Niemann-Pick, Gaucher, LCAT deficiency, hyperlipoproteinemia, myeloproliferative disorders, ITP | Requires exclusion workup for storage disease, hematologic neoplasm, ineffective erythropoiesis, nutrition/drug causes | Primary form is rare; no robust prevalence estimate found | Bhardwaj 2020; Caetano 2016; El Euch 2013 | https://doi.org/10.7759/cureus.10396 ; https://doi.org/10.23937/2469-5807/1510019 ; https://doi.org/10.4236/ojim.2013.31005 | (pqac-00000000, pqac-00000006, pqac-00000002, pqac-00000005) |
| Typical clinical phenotype in reported primary SBHS | Most consistent reported features are splenomegaly, often hepatomegaly, thrombocytopenia/hemorrhagic diathesis; pancytopenia can occur. Hypertriglyceridemia is part of the classic primary syndrome description. | Primary SBHS phenotype; inherited lipemic splenomegaly concept | Clinical exam plus CBC, lipid profile, liver studies; marrow biopsy often prompted by cytopenias/splenomegaly | Hepatomegaly reported in ~60% of primary cases in review literature | Caetano 2016; Bhardwaj 2020 | https://doi.org/10.23937/2469-5807/1510019 ; https://doi.org/10.7759/cureus.10396 | (pqac-00000001, pqac-00000000) |
| Reported prognosis in primary SBHS literature | Course is usually benign/chronic, but severe organ infiltration can occur; fatal liver failure/cirrhosis is the major feared complication in older primary SBHS literature. | Primary SBHS | Monitor liver involvement, cytopenias, organomegaly | Roughly 15% of cases reported to develop fatal liver failure/cirrhosis | Caetano 2016; Fernández 2023; El Euch 2013 | https://doi.org/10.23937/2469-5807/1510019 ; https://doi.org/10.48057/hematologa.v27i2.519 ; https://doi.org/10.4236/ojim.2013.31005 | (pqac-00000002, pqac-00000008, pqac-00000011, pqac-00000005) |
| Niemann-Pick / ASMD context | Sea-blue histiocytes are strongly associated with Niemann-Pick spectrum disorders in pathology practice. Older literature proposed “type F”/sea-blue histiocytosis for a relatively benign form without neurologic involvement, but this designation has fallen out of favor. | SMPD1-related acid sphingomyelinase deficiency (ASMD/NPD A/B); historical NPD “type F” | Bone marrow, liver, spleen, lung pathology may show foamy histiocytes/sea-blue histiocytes | NPD types A/B combined prevalence in review excerpt ~1 in 250,000; historical type F label no longer favored | Ferreira & Gahl 2017; Günay 2012; Tirelli 2024 | https://doi.org/10.3233/trd-160005 ; https://doi.org/10.5578/tt.2215 ; https://doi.org/10.3390/biom14020211 | (pqac-00000018, pqac-00000021, pqac-00000003, pqac-00000014) |
| Niemann-Pick type C context | In NP-C, pathology may include foam cells or sea-blue histiocytes in many tissues, but these are not specific and may be absent if visceromegaly is lacking; modern diagnosis relies on molecular and biochemical testing. | NPC1, NPC2 | Marrow/spleen biopsy can support suspicion; filipin-cholesterol staining in cultured fibroblasts; plasma oxysterols by LC-MS/MS; molecular testing | NP-C prevalence ~1 in 150,000 | Ferreira & Gahl 2017 | https://doi.org/10.3233/trd-160005 | (pqac-00000017, pqac-00000019) |
| ASMD genetics and modern therapy context | ASMD/NPD A and B are autosomal recessive disorders due to SMPD1 mutations causing acid sphingomyelinase deficiency; olipudase alfa is the first approved disease-modifying therapy. This is relevant because sea-blue histiocytes can be a marrow/tissue clue to underlying ASMD. | SMPD1 | Enzyme assay for acid sphingomyelinase; molecular confirmation; HRCT/BAL/biopsy for lung disease when indicated | No SBHS-specific treatment; ASMD has disease-modifying therapy | Tirelli 2024 | https://doi.org/10.3390/biom14020211 | (pqac-00000014) |
| Other associated disorders | Reviews/case reports list Gaucher disease, LCAT deficiency, cholesterol ester storage disease, Tangier disease, severe hypertriglyceridemia/hyperlipoproteinemia, chronic myelogenous leukemia, myelodysplastic syndromes, thalassemia, ITP, and prolonged total parenteral nutrition as associations. | Gaucher (GBA context not detailed in gathered evidence), LCAT deficiency, lipid disorders, hematologic disorders | Directed enzyme assays, lipid studies, hematology workup, marrow review, medication/nutrition history | No unified frequency across causes | Caetano 2016; El Euch 2013; Bhardwaj 2020; Fernández 2023 | https://doi.org/10.23937/2469-5807/1510019 ; https://doi.org/10.4236/ojim.2013.31005 ; https://doi.org/10.7759/cureus.10396 ; https://doi.org/10.48057/hematologa.v27i2.519 | (pqac-00000002, pqac-00000005, pqac-00000000, pqac-00000011) |
| Parenteral nutrition–associated acquired sea-blue histiocytosis | 2023 case report documents marrow sea-blue histiocytes in a patient on prolonged parenteral nutrition, supporting a real-world acquired form due to abnormal long-chain fatty acid/lipid handling and reticuloendothelial deposition. | Acquired/non-Mendelian mimic of SBHS | Bone marrow aspirate/biopsy showed macrophages with blue intracytoplasmic granules; clinical correlation with liver failure, hypertriglyceridemia, pancytopenia | Hypertriglyceridemia in case: 332 mg/dL; ferritin >1500 ng/mL | Fernández 2023 | https://doi.org/10.48057/hematologa.v27i2.519 | (pqac-00000011, pqac-00000022, pqac-00000023) |
| Practical diagnostic approach | Current reviews on hepatosplenomegaly/LSDs recommend molecular testing as the preferred confirmatory test over biopsy when LSD is suspected, usually accompanied by enzymatic testing when feasible; biopsy remains useful as a clue when sea-blue histiocytes are discovered unexpectedly. | LSD differential includes NPC, ASMD, Gaucher, CESD | Imaging for hepatosplenomegaly; CBC/liver tests; molecular testing; enzyme testing; biopsy as supportive rather than definitive in many LSDs | LSD collective incidence ~1 in 5000 live births | Serrano 2024; Ferreira & Gahl 2017 | https://doi.org/10.3390/jcm13051465 ; https://doi.org/10.3233/trd-160005 | (pqac-00000015, pqac-00000017, pqac-00000013) |
| Pulmonary/visceral involvement | Sea-blue histiocytes/foamy macrophages can infiltrate liver, spleen, marrow, lung, and lymphoid organs; pulmonary involvement is uncommon in primary sea-blue histiocytosis but recognized in Niemann-Pick/ASMD. | Particularly ASMD/Niemann-Pick; historical primary SBHS reports | BAL, lung biopsy, HRCT, pulmonary function testing in symptomatic patients | No general percentage reported; lung disease more frequent in NPD type B than C | Günay 2012; Tirelli 2024; Fernández 2023 | https://doi.org/10.5578/tt.2215 ; https://doi.org/10.3390/biom14020211 ; https://doi.org/10.48057/hematologa.v27i2.519 | (pqac-00000003, pqac-00000014, pqac-00000011) |


*Table: This table consolidates the gathered evidence on Sea-Blue Histiocyte Syndrome/sea-blue histiocytosis, emphasizing that it is primarily a histopathologic pattern with a rare primary syndrome and many secondary causes. It also links the finding to modern lysosomal disease diagnostics and therapies relevant to the differential diagnosis.*